NCCAM Strategy Stresses Steps Toward Better Trials For Supplements
This article was originally published in The Tan Sheet
The nutritional product industry expects benefits from the National Center for Complementary and Alternative Medicine draft strategic plan's emphasis on funding more preliminary research needed to launch informative clinical trials on supplement ingredients
You may also be interested in...
Researchers conclude DHA fatty acid supplementation does not treat Alzheimer's disease, but they say the omega-3 substance may help prevent the onset of dementia.
A National Center for Complementary and Alternative Medicine report on CAM spending could prompt more research into the health benefits consumers are increasingly seeking from dietary supplements and other products and services not considered part of conventional medicine
FDA's apparent contention that results from randomized controlled trials invalidate conflicting information from observational studies on the effects of nutrients reflects "an intrinsic bias" within the agency or "a lack of fundamental understanding of research methods," according to the Council for Responsible Nutrition